Compare AEC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEC | MDWD |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 193.3M |
| IPO Year | N/A | 2013 |
| Metric | AEC | MDWD |
|---|---|---|
| Price | $5.35 | $16.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 40.1K | ★ 102.9K |
| Earning Date | 05-01-2015 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $48.92 |
| Revenue Next Year | N/A | $35.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.42 | $14.90 |
| 52 Week High | $12.49 | $22.51 |
| Indicator | AEC | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 45.04 |
| Support Level | $5.50 | $14.90 |
| Resistance Level | $6.04 | $18.62 |
| Average True Range (ATR) | 0.46 | 0.83 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 37.27 | 41.22 |
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One. The company's geographical segments are Canada and the United States.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.